title: For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top.
abstract: The stromal immunoglobulin kappa chain (IGKC) has been validated as an immunologic biomarker of prognosis and response to therapy in human breast cancer and other cancers. This validation emphasizes the key role of humoral immunity in control of cancer progression and has major implications for determining prognosis of patients with cancer.
authors.affiliation: Department of Pathology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA. whitesidetl@upmc.edu
authors.forename: Theresa L
authors.initials: TL
authors.lastname: Whiteside
authors.forename: Soldano
authors.initials: S
authors.lastname: Ferrone
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D015179:Colorectal Neoplasms / Q000235:genetics*; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D007136:Immunoglobulins / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; C014609:IgK; D007136:Immunoglobulins